Skip to content
DataLookout
Menu

BCIRT-01NCT05975307

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Secondary endpoints: 7 to 6
  2. Notable Primary completion pushed from Dec 31, 2025 to Dec 31, 2026
    • Eligibility criteria shortened, about 2 words
  3. Notable Primary completion date: Dec 31, 2025 to Dec 31, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Enrollment target: 71 to 64
    • Secondary endpoints: details revised at 1 of 7 entries
    • Study description revised
  4. Minor Enrollment target: 64 to 71
    • Primary completion date: Aug 31, 2025 to Dec 31, 2025
    • Secondary endpoints revised (7)
    v7
  5. Minor Secondary endpoints: 8 to 7v6
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Primary completion date: Dec 31, 2024 to Aug 31, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  2. Minor Start date changed from estimate of Nov 21, 2023 to Dec 1, 2023v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Aug 1, 2023 to Nov 21, 2023
    • Site details revised
    v3
  4. Minor Secondary endpoints: details revised at 1 of 8 entries
    • Study description expanded, about 5 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Clinical complete response (cCR) rate
Timeframe: When the eligible patients complete the treatment and followed-up for half a year

Secondary (6)

Overall survival (OS)
Bladder-intact event-free survival (BI-EFS)
Disease-free survival (DFS)
Local recurrence (LR) rate
Incidence of grade 3/4 (G3/4) toxicities
Show 1 moreShow less
Bladder function

Arms and interventions

Toripalimab plus chemoradiationExperimental

This study has only single arm in which the patients will receive neoadjuvant chemotherapy plus anti-PD-1 therapy (toripalimab), followed by radiotherapy plus concurrent anti-PD-1 therapy

Drugs: Toripalimab, Gemcitabine, Cisplatin, Carboplatin

Radiation: Intensity-modulated radiation therapy

Sites

1 site in 1 country

  • Cancer Center, Sun Yat-sen UniversityGuangzhou, Guangdong, China